243 related articles for article (PubMed ID: 17511032)
21. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.
Halpin SJ; Hamlin PJ; Greer DP; Warren L; Ford AC
World J Gastroenterol; 2013 Feb; 19(7):1091-7. PubMed ID: 23467174
[TBL] [Abstract][Full Text] [Related]
23. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
[TBL] [Abstract][Full Text] [Related]
24. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
Gies N; Kroeker KI; Wong K; Fedorak RN
Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
[TBL] [Abstract][Full Text] [Related]
25. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial.
Van Assche G; Vermeire S; Ballet V; Gabriels F; Noman M; D'Haens G; Claessens C; Humblet E; Vande Casteele N; Gils A; Rutgeerts P
Gut; 2012 Feb; 61(2):229-34. PubMed ID: 21948942
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
Christensen KR; Steenholdt C; Brynskov J
Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab in active ulcerative colitis: a "real-life" observational study.
; Armuzzi A; Biancone L; Daperno M; Coli A; Pugliese D; Annese V; Aratari A; Ardizzone S; Balestrieri P; Bossa F; Cappello M; Castiglione F; Cicala M; Danese S; D'Incà R; Dulbecco P; Feliciangeli G; Fries W; Genise S; Gionchetti P; Gozzi S; Kohn A; Lorenzetti R; Milla M; Onali S; Orlando A; Papparella LG; Renna S; Ricci C; Rizzello F; Sostegni R; Guidi L; Papi C
Dig Liver Dis; 2013 Sep; 45(9):738-43. PubMed ID: 23683530
[TBL] [Abstract][Full Text] [Related]
28. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants.
Reinisch W; Sandborn WJ; Panaccione R; Huang B; Pollack PF; Lazar A; Thakkar RB
Inflamm Bowel Dis; 2013 Jul; 19(8):1700-9. PubMed ID: 23665965
[TBL] [Abstract][Full Text] [Related]
29. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
30. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.
Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
Aliment Pharmacol Ther; 2014 Apr; 39(7):660-71. PubMed ID: 24506179
[TBL] [Abstract][Full Text] [Related]
31. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
[TBL] [Abstract][Full Text] [Related]
32. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.
McDermott E; Murphy S; Keegan D; O'Donoghue D; Mulcahy H; Doherty G
J Crohns Colitis; 2013 Mar; 7(2):150-3. PubMed ID: 22520592
[TBL] [Abstract][Full Text] [Related]
34. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.
Yamamoto-Furusho JK; Uzcanga LF
Dig Surg; 2008; 25(5):383-6. PubMed ID: 19005257
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years.
Barreiro-de Acosta M; Lorenzo A; Dominguez-Muñoz JE
World J Gastroenterol; 2009 Aug; 15(30):3814-6. PubMed ID: 19673025
[TBL] [Abstract][Full Text] [Related]
36. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
[TBL] [Abstract][Full Text] [Related]
37. Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis.
Feagan BG; Sandborn WJ; Lazar A; Thakkar RB; Huang B; Reilly N; Chen N; Yang M; Skup M; Mulani P; Chao J
Gastroenterology; 2014 Jan; 146(1):110-118.e3. PubMed ID: 24067881
[TBL] [Abstract][Full Text] [Related]
38. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.
Zacharias P; Damião AOMC; Moraes AC; Teixeira FV; Ludvig JC; Nones RB; Saad-Hossne R; Sassaki LY; Silva RPLD; Facchin L; Olandoski M; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):321-327. PubMed ID: 28977114
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.
Kohn A; Prantera C; Pera A; Cosintino R; Sostegni R; Daperno M
Dig Liver Dis; 2002 Sep; 34(9):626-30. PubMed ID: 12405248
[TBL] [Abstract][Full Text] [Related]
40. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease.
Sandborn WJ; Hanauer S; Loftus EV; Tremaine WJ; Kane S; Cohen R; Hanson K; Johnson T; Schmitt D; Jeche R
Am J Gastroenterol; 2004 Oct; 99(10):1984-9. PubMed ID: 15447761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
